Most Recent
Sydney-based research foundation Brien Holden Vision Institute has filed a lawsuit alleging three senior researchers misused confidential information when they jumped ship to a rival research group and filed applications to patent seven inventions for opthalmic lenses designed to treat myopia allegedly based on that information.
Evidence of an outdated management approach and bullying -- which included threatening defamation proceedings against two junior lawyers that complained about her -- appear to be responsible for the ousting of a former senior Piper Alderman partner, not her sex, a judge has found.
A former Piper Alderman partner has lost her bid to bring sex discrimination claims against the partners of the law firm, but can still proceed with her other claims.
Buffet restaurant pioneer Sizzler is seeking a quick win in its trade mark stoush with Brisbane-based Burger Urge tossed, telling a court it will be seeking summary judgment in its favour.
Generic drug maker Sandoz has successfully appealed a $26.3 million judgment finding it infringed a patent owned by rival H Lundbeck relating to the top-selling antidepressant Lexapro.
Tile maker Ceramiche Caesar has prevailed in its challenge to a judge's ruling allowing building products manufacturer Caesarstone to register two trade marks despite a finding that they were deceptively similar to one of its marks.
Coffee capsule maker Caffitaly is challenging a ruling that revoked three patents at the centre of an intellectual property war with rival One Collective.
Mylan Health has lost its challenge to a ruling that invalidated three patents related to its blockbuster cholesterol drug Lipidil, despite the appeals court finding the primary judge had erred by ruling that proof of intention was required for Swiss-style claims.
Drug manufacturer Janssen wants to expand its high stakes case against Juno Pharmaceuticals over its HIV drug Prezista, alleging Juno's plans to launch a generic version of the drug threaten another one of its patents.
Ariosa Diagnostics is fighting to revoke a patent for noninvasive prenatal test owned by Sequenom, arguing it merely describes how to extract "incorporeal" genetic information that is naturally found within the DNA of an unborn foetus.